Thierry Van Effelterre
Overview
Explore the profile of Thierry Van Effelterre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
319
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Postma M, Cheng C, Buyukkaramikli N, Hernandez Pastor L, Vandersmissen I, Van Effelterre T, et al.
Vaccines (Basel)
. 2023 Nov;
11(11).
PMID: 38006005
We have read the commentary from Baudouin Standaert [...].
2.
Postma M, Cheng C, Buyukkaramikli N, Hernandez Pastor L, Vandersmissen I, Van Effelterre T, et al.
Vaccines (Basel)
. 2023 May;
11(5).
PMID: 37243094
Respiratory syncytial virus (RSV) is a leading cause of acute respiratory infection (ARI) in older adults. This study used a static, cohort-based decision-tree model to estimate the public health and...
3.
Bisanzio D, Davis A, Talbird S, Van Effelterre T, Metz L, Gaudig M, et al.
Vaccine
. 2022 Dec;
41(3):684-693.
PMID: 36526505
Introduction: Nonpharmaceutical interventions (NPI) and ring vaccination (i.e., vaccination that primarily targets contacts and contacts of contacts of Ebola cases) are currently used to reduce the spread of Ebola during...
4.
Bockstal V, Leyssen M, Heerwegh D, Spiessens B, Robinson C, Stoop J, et al.
NPJ Vaccines
. 2022 Nov;
7(1):156.
PMID: 36450746
Without clinical efficacy data, vaccine protective effect may be extrapolated from animals to humans using an immunologic marker that correlates with protection in animals. This immunobridging approach was used for...
5.
Potluri R, Kumar A, Oriol-Mathieu V, Van Effelterre T, Metz L, Bhandari H
BMC Infect Dis
. 2022 Oct;
22(1):769.
PMID: 36192683
Background: Protection by preventive Ebola vaccines has been demonstrated in clinical trials, but a complete picture of real-world effectiveness is lacking. Our previous study modeling the impact of preventively vaccinating...
6.
Roozendaal R, Hendriks J, Van Effelterre T, Spiessens B, Dekking L, Solforosi L, et al.
NPJ Vaccines
. 2020 Dec;
5(1):112.
PMID: 33335092
It has been proven challenging to conduct traditional efficacy trials for Ebola virus (EBOV) vaccines. In the absence of efficacy data, immunobridging is an approach to infer the likelihood of...
7.
Balelli I, Pasin C, Prague M, Crauste F, Van Effelterre T, Bockstal V, et al.
J Theor Biol
. 2020 Mar;
495:110254.
PMID: 32205143
The 2014-2016 Ebola outbreak in West Africa has triggered accelerated development of several preventive vaccines against Ebola virus. Under the EBOVAC1 consortium, three phase I studies were carried out to...
8.
Pasin C, Balelli I, Van Effelterre T, Bockstal V, Solforosi L, Prague M, et al.
J Virol
. 2019 Jun;
93(18).
PMID: 31243126
The Ebola vaccine based on Ad26.ZEBOV/MVA-BN-Filo prime-boost regimens is being evaluated in multiple clinical trials. The long-term immune response to the vaccine is unknown, including factors associated with the response...
9.
Van Effelterre T, Guignard A, Marano C, Rojas R, Jacobsen K
Hum Vaccin Immunother
. 2017 May;
13(8):1942-1951.
PMID: 28481680
Background: Many low- to middle-income countries have completed or are in the process of transitioning from high or intermediate to low endemicity for hepatitis A virus (HAV). Because the risk...
10.
Pan-Ngum W, Kinyanjui T, Kiti M, Taylor S, Toussaint J, Saralamba S, et al.
Vaccine
. 2016 Dec;
35(2):403-409.
PMID: 27914740
Background: Respiratory syncytial virus (RSV) is the major viral cause of infant and childhood lower respiratory tract disease worldwide. Defining the optimal target product profile (TPP) is complicated due to...